MUTATIONAL LANDSCAPE OF RELAPSED ACUTE PROMYELOCYTIC LEUKEMIA
EHA Learning Center, Valentina Alfonso, 214635
THE ROLE OF THE TRANSCRIPTION FACTOR GFI1 IN LEUKEMIA GENOME STABILITY AND EVOLUTION
EHA Learning Center, Daria Frank, 214636
VEGFC ANTIBODY TREATMENT: A NEW DIFFERENTIATION THERAPY FOR AML
EHA Learning Center, Kim Kampen, 214637
IMPACT OF NPM1 MRD STATUS AFTER TWO CYCLES OF INTENSIVE CHEMOTHERAPY TO INFORM TYPE OF POST-REMISSION THERAPY: A STUDY OF THE AML STUDY GROUP (AMLSG)
EHA Learning Center, Silke Kapp-Schwoerer, 214651
DISTINCT DNA METHYLATION PROFILES IN DIFFERENT CYTOGENETIC SUBGROUPS OF CHRONIC LYMPHOCYTIC LEUKEMIA: THE INTRIGUING CASE OF TRISOMY 12
EHA Learning Center, MARIA TSAGIOPOULOU, 214652
BIALLELIC INACTIVATION OF ATM AND BIRC3 IN DEL(11Q) CELLS DRIVES GENOMIC INSTABILITY AND TUMOR EXPANSION IN CRISPR/CAS9-GENERATED MODELS OF CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Miguel Quijada Alamo, 214653
TITLE: PROGNOSTIC IMPACT OF THE BCR/ABL1-LIKE SIGNATURE IN ADULT B-LINEAGE ALL. FIRST ANALYSIS OF THE GIMEMA LAL1913 PROTOCOL
EHA Learning Center, Sabina Chiaretti, 215235
CHARACTERIZATION OF PEDIATRIC T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH DNA METHYLATION STATUS
EHA Learning Center, Shunsuke Kimura, 215236
THE PHILADELPHIA-LIKE SUBTYPE IN CHILDREN WITH FIRST RELAPSE OF B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: A STUDY OF THE GERMAN ALL-REZ BFM 2002 TRIAL
EHA Learning Center, Malwine Pogodzinski, 215237
LOW MIR-151 AND MIR-451 LEVELS IN BONE MARROW AT DIAGNOSIS IS CONFIRMED AS A PROGNOSTIC FACTOR FOR RELAPSE OF B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS FROM THE AIEOP 2000 CLINICAL TRIAL
EHA Learning Center, Jennifer Yarden, 215252
THE CELL SURFACE PROTEIN VANIN-2 IDENTIFIES AGGRESSIVE SUBTYPES OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Virginia Rodriguez Martinez, 215253
NILOTINIB COMBINED WITH LOWER-INTENSITY CHEMOTHERAPY FOR FRONT-LINE TREATMENT OF YOUNGER ADULTS WITH PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): INTERIM ANALYSIS OF THE GRAAPH-2014 TRIAL
EHA Learning Center, Yves Chalandon, 215254
FLT3-ITD ANALYSIS ON RNA CONFERS ENHANCED SENSITIVITY AND ALLOWS EARLIER RELAPSE PREDICTION
EHA Learning Center, Elisabeth Oppliger Leibundgut, 215269
PHARMACOLOGIC INHIBITION OF CELLULAR METABOLIC PROCESSES IMPACTED BY AGING SENSITIZE ACUTE MYELOID LEUKEMIA (AML) CELLS TO THE NOVEL LIPOATE DERIVATIVE CPI-613
EHA Learning Center, Timothy Pardee, 215270
GENOMIC CHARACTERIZATION OF DIAGNOSTIC AND REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA SAMPLES THROUGH A NEXT GENERATION SEQUENCING (NGS) PANEL OF 62 GENES
EHA Learning Center, Diego Carbonell, 215271
GENOMIC-DRIVEN AND FUNCTIONAL ALTERATIONS IN ENERGY, AMINO ACID AND LIPID METABOLISM IN ACUTE MYELOID LEUKEMIA BLASTS AND STEM PROGENITOR CELLS
EHA Learning Center, Giorgia Simonetti, 215285
THE CALCIUM BINDING PROTEIN S100A8/S100A9 COMPLEX IS ASSOCIATED WITH DRUG RESISTANCE IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Riikka Karjalainen, 215286
A HIGH RISK PEDIATRIC AML SUBTYPE PRESENTS A DIAGNOSTIC CHALLENGE-A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP AAML0531 STUDY
EHA Learning Center, Timothy P Singleton, 215288
EVALUATION OF THE DRUG INTERACTION POTENTIAL OF PRACINOSTAT, A NOVEL HISTONE DEACETYLASE (HDAC) INHIBITOR, WITH CYP1A2 INDUCER CIGARETTE SMOKING AND CIPROFLOXACIN, A CYP1A2 INHIBITOR
EHA Learning Center, Alberto Bernareggi, 215302
SINGLE CENTRE REAL-LIFE EXPERIENCE OF HYPOMETHYLATING AGENTS WITH OR WITHOUT DLI AS SALVAGE THERAPY FOR ACUTE MYELOID LEUKEMIA RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION.
EHA Learning Center, Davide Lazzarotto, 215303
CONSOLIDATION CHEMOTHERAPY PREVENTS RELAPSE BY INDIRECTLY REGULATING BONE MARROW ADIPOGENESIS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
EHA Learning Center, Hanyan Liu, 215304
CELL-FREE DNA MONITORING OF MINIMAL RESIDUAL DISEASE IN AML USING A TARGETED NGS GENE PANEL
EHA Learning Center, Zhiyi Xie, 215318
INTRA-PATIENT DOSE-ESCALATION STUDY OF CRENOLANIB MAINTENANCE THERAPY IN PATIENTS WITH FLT3 MUTANT AML WHO HAD UNDERGONE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLO-HSCT)
EHA Learning Center, Betul Oran, 215319
CONSOLIDATION THERAPY WITH PONATINIB IN COMBINATION WITH CYTARABINE IN PATIENTS FOR FLT3-ITD ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION.
EHA Learning Center, Philippe Rousselot, 215320
BIOMARKER ANALYSIS OF TISAGENLECLEUCEL PRE-INFUSION BIOPSIES OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
EHA Learning Center, Ulrich Jäger, 215334
ACALABRUTINIB IN COMBINATION WITH THE PI3Kδ INHIBITOR ACP-319 IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES.
EHA Learning Center, Paul M. Barr, 215335
TIME TO RELAPSE OF MANTLE CELL LYMPHOMA AFTER INTENSIVE HIGH DOSE CYTARABINE CONTAINING REGIMENS DEFINES PATIENTS RISK FOR DEATH: AN ANALYSIS FROM CENTERS OF THE FONDAZIONE ITALIANA LINFOMI
EHA Learning Center, Carlo Visco, 215336
ON THE APPLICABILITY OF RHOA GLY17VAL POINT MUTATION TESTING FOR A DIFFERENTIAL DIAGNOSIS OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
EHA Learning Center, Yulia Sidorova, 215350
THE ADDITION OF ROMIDEPSIN TO CHOEP FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND TRANSPLANTATION IS FEASIBLE IN UNTREATED PERIPHERAL T-CELL LYMPHOMAS: RESULTS OF PHASE IB FIL-PTCL13
EHA Learning Center, Annalisa Chiappella, 215351
A PHASE I, MULTICENTER, OPEN-LABEL DOSE-ESCALATION STUDY OF CC-122, A NOVEL CEREBLON-MODULATING AGENT, IN ADULT JAPANESE PATIENTS WITH ADVANCED NON-HODGKIN LYMPHOMA OR SOLID TUMOR
EHA Learning Center, Kazuhito Yamamoto, 215352
HAEMOSTATIC ABNORMALITIES OR DEFECTS IN GREEK PATIENTS WITH GAUCHER DISEASE
EHA Learning Center, Veroniki Komninaka, 215366
THALIDOMIDE USE IN HEREDITARY HEMORRHAGIC TELANGIECTASIA: A RETROSPECTIVE EVALUATION OF THE PATIENTS
EHA Learning Center, Mehmet Baysal, 215367
DIAGNOSIS AND MANAGEMENT OF ACQUIRED VON WILLEBRAND DISEASE. A SINGLE CENTER EXPERIENCE
EHA Learning Center, Cristina Santoro, 215368
ADULT PATIENTS WITH ACQUIRED PURE RED CELL APLASIA: COMBINATION OF CYCLOSPORINE A AND CORTICOSTEROIDS PRODUCE BETTER CR
EHA Learning Center, Guangsheng He, 215382
MANAGEMENT OF PATIENTS WITH SEVERE APLASTIC ANAEMIA WHO ARE REFRACTORY TO PLATELET TRANSFUSIONS USING LEUKOCYTE CONCENTRATES
EHA Learning Center, jiali Huo, 215383
IRON OVERLOAD AND MANAGEMENT IN PATIENTS WITH DIAMOND BLACKFAN ANEMIA
EHA Learning Center, Sule Unal, 215384
ILT3/DELTEX-1/SHIP-1 AS A NOVEL INHIBITORY AXIS CONTROLLING B CELL RECEPTOR SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Anna Kabanova, 215399
DETIN: OVERCOMING TUMOR IN NORMAL CONTAMINATION.
EHA Learning Center, Amaro Taylor-Weiner, 215400
TRACKING THE MINOR CLONES IN OLIGOCLONAL CHRONIC LYMPHOCYTIC LEUKEMIA USING HIGH-THROUGHPUT IMMUNOPROFILING
EHA Learning Center, Kamila Stranska, 215401
“IMMUNO-FLOW-FISH”: HIGH THROUGHPUT FLUORESCENCE IN SITU HYBRIDISATION OF PHENOTYPED CHRONIC LYMPHOCYTIC LEUKAEMIA BY IMAGING FLOW CYTOMETRY FOR CLINICAL APPLICATION
EHA Learning Center, Wendy Erber, 215415
EXPRESSION OF ANTIGENS INVOLVED IN THE FORMATION OF AN IMMUNOLOGICAL SYNAPSE IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Yulia Davydova, 215416
FREQUENCY OF TYPICAL AND ATYPICAL FUSION TRANSCRIPTS IN PATIENTS WITH BCR-ABL1-POSITIVE LEUKEMIAS – A SINGLE INSTITUTION STUDY
EHA Learning Center, Gueorgui Balatzenko, 215431
PATIENT-SPECIFIC BCR-ABL1 GENOMIC FUSION ANALYSIS OF MINIMAL RESIDUAL DISEASE OF CML PATIENTS ELIGIBLE FOR TKI STOPPING SIGNIFICANTLY OUTPERFORMED MRNA DETECTION EITHER BY QPCR OR DIGITAL PCR
EHA Learning Center, Katerina Machova Polakova, 215432
LONG-TERM TREATMENT RESPONSE BASED ON SEVERITY OF GAUCHER DISEASE TYPE 1 AT BASELINE IN TREATMENT-NAÏVE ADULT PATIENTS AFTER 8 YEARS OF TREATMENT WITH ORAL ELIGLUSTAT
EHA Learning Center, Elena Lukina, 215448
COMBINED EMA-BINDING TEST AND OSMOTIC GRADIANT EKTACYTOMETRY SIGNIFICANTLY IMPROVE THE LABORATORY DIAGNOSIS OF HEREDITARY SPHEROCYTOSIS
EHA Learning Center, Andreas Glenthøj, 215449
SIGNIFICANT ARI-0001 (A3B1:CD8:4-1BB:CD3Z CAR19) CELL EXPANSION IN A PATIENT WITH REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA THROUGH PRE-LYMPHOAPHERESIS IBRUTINIB ADMINISTRATION.
EHA Learning Center, Valentín Ortiz-Maldonado Gibson, 215464
HIGH BASELINE FERRITIN IS ASSOCIATED WITH GRADE 2 CRS REQUIRING TOCILIZUMAB OR GRADE ≥ 3 CRS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH BB2121 ANTI-BCMA CAR T CELLS
EHA Learning Center, Jesus Berdeja, 215465
IMPACT OF SPLENECTOMY ON CD34+ BLOOD COUNT
EHA Learning Center, Irina Galtseva, 215480
VERY LATE RELAPSES (VLRS) IN HODGKIN LYMPHOMA (HL) OCCURING ≥5 YEARS AFTER INITIAL TREATMENT WITH CHEMOTHERAPY ± RADIOTHERAPY (CT±RT): PATTERN OF RISK OVER 35 YEARS AND THE SIGNIFICANCE OF HISTOLOGY
EHA Learning Center, Theodoros Vassilakopoulos, 215481
OVERALL SURVIVAL OF MANTLE CELL LYMPHOMA (MCL) PATIENTS HAS BEEN SIGNIFICANTLY IMPROVED DURING THE TIME, MAINLY DUE TO THE RITUXIMAB MAINTENANCE IN ELDERLY POPULATION, REAL WORLD DATA.
EHA Learning Center, Marek Trneny, 215496
IBRUTINIB FOR THE TREATMENT OF BING-NEEL SYNDROME
EHA Learning Center, Jorge Castillo, 215497
TETANUS, DIPHTHERIA AND POLIO IMMUNITY AFTER CHEMOTHERAPY AND RITUXIMAB IN PATIENTS WITH LEUKEMIA AND LYMPHOMA
EHA Learning Center, Sigrun Einarsdottir, 215513
THE DIAGNOSTIC UTILITY AND SENSITIVITY OF THE XPERT® MTB/RIF ASSAY IN DIAGNOSING MYCOBACTERIUM TUBERCULOSIS IN BONE MARROW ASPIRATE SPECIMENS
EHA Learning Center, Nadhiya Subramony, 215514
ACERULOPLASMINAEMIA - THE EXTREMELY RARE ALSO EXISTS
EHA Learning Center, João Gomes, 215530
IT TAKES A LOT OF IRON TO AVOID TRANSFUSION
EHA Learning Center, Magda Jabbar Al-Obaidi, 215531
COMPLETE BLOOD COUNT- BASED SCORE FOR THE DIAGNOSIS AND PROGNOSIS OF MYELODYSPLASTIC SYNDROMES IN CYTOPENIC PATIENTS
EHA Learning Center, Marion Eveillard, 215546
AUTOPHAGY IN MYELODYSPLASTIC SYNDROMES: THE ROLE OF HIF-1A/REDD1 MOLECULAR PATHWAY
EHA Learning Center, Ioanna STERGIOU, 215547
SEVERE THROMBOCYTOPENIA AS A PREDICTOR OF SURVIVAL AND RESPONSE TO HYPOMETHYLATING AGENTS: DATA FROM A LATIN-AMERICAN COHORT
EHA Learning Center, Carolina Lazzarino, 215563
TLR4 SIGNALING DRIVES MESENCHYMAL STEM CELLS (MSC) COMMITMENT TO PROMOTE TUMOR MICROENVIRONMENT TRANSFORMATION IN MULTIPLE MYELOMA
EHA Learning Center, Cesarina Giallongo, 215564
JAGGED1/2 INHIBITION PROMOTES TUMOR CELLS RESPONSE TO BORTEZOMIB IN A ZEBRAFISH MODEL OF MULTIPLE MYELOMA
EHA Learning Center, Maria Teresa Palano, 215579
TGFΒ INHIBITION IN COMBINATION WITH CHEMOTHERAPY REPAIRS EXISTING LYTIC BONE LESIONS IN A NOVEL PLATEAU PHASE MODEL OF MULTIPLE MYELOMA
EHA Learning Center, Andrew Chantry, 215580
SKY92 RISK STRATIFICATION AT RELAPSE PROVIDES ADDITIONAL PROGNOSTIC INFORMATION FOR STANDARD-RISK MULTIPLE MYELOMA PATIENTS
EHA Learning Center, Rowan Kuiper, 215595
CARFILZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE IN TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PRELIMINARY RESULT OF SGHMM1 TRIAL, HIGH-RISK COHORT (NCT02217163)
EHA Learning Center, Chandramouli Nagarajan, 215596
SERIAL SERUM FREE LIGHT CHAIN ASSAY CAN REDUCE THE NEED FOR 24-HOUR URINE PROTEIN ASSESSMENT FOR RESPONSE ASSESSMENT IN MULTIPLE MYELOMA
EHA Learning Center, Marcella Tschautscher, 215611
NOVEL THERAPIES DIFFERENTIALLY IMPACT POLYCLONAL IMMUNOGLOBULIN RECOVERY IN MYELOMA PATIENTS: A LONGITUDINAL STUDY
EHA Learning Center, Mauricette Michallet, 215612
MULTIPLE MYELOMA IN PATIENTS UNDER 40 YEARS OLD: A RETROSPECTIVE ANALYSIS FROM THE INTERGOUPE FRANCOPHONE DU MYELOME (IFM).
EHA Learning Center, Alexis Caulier, 215627
AMPLICON NEXT-GENERATION SEQUENCING (NGS) OF REARRANGED IMMUNOGLOBULIN (IG) LOCI IS ADVANTAGEOUS FOR CLONAL MARKER IDENTIFICATION AND MINIMAL RESIDUAL DISEASE (MRD) DETECTION IN MULTIPLE MYELOMA (MM).
EHA Learning Center, Michaela Kotrová, 215628
BOARDING ON THE SECRETARY PATHWAY IS REQUIRED FOR THE ONCOGENIC PROPERTY OF MUTANT CALRETICULIN
EHA Learning Center, Marito Araki, 215643
PHARMACOLOGICAL INHIBITION OF IGF1R/IRS TARGETING STAT3/STAT5 SIGNALING HAS ANTI-NEOPLASTIC EFFECTS IN JAK2 V617F MYELOPROLIFERATIVE NEOPLASMS
EHA Learning Center, Jaqueline Cristina Fernandes, 215644
LIMITATIONS OF PREVIOUS PROGNOSTIC MODELS FOR THROMBOSIS AND EXPLORATION OF MODIFIED MODELS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
EHA Learning Center, Yoshinori Hashimoto, 215659
SERVICE EVALUATION OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM AND SPLANCHNIC VEIN THROMBOSIS (MPN-SVT).
EHA Learning Center, Sarah Wharin, 215660
SPLENIC MARGINAL ZONE B-CELL LYMPHOMAS DEPENDS ON PROGRAMMED DEATH-LIGAND 1 FOR CLONAL EMERGENCE AND ARE CONTROLLED BY T-CELLS FOR PROLIFERATION RATE
EHA Learning Center, Nathalie FAUMONT, 215676
MECHANISMS CONFERRING RESISTANCE TO VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA AND MANTLE CELL LYMPHOMA
EHA Learning Center, Daniela Steinbrecher, 215677
PREDICTIVE FACTORS FOR DEVELOPING SYSTEMIC LUPUS ERYTHEMATOSUS AFTER CHILDHOOD AUTOIMMUNE CYTOPENIA
EHA Learning Center, Nathalie Aladjidi, 215693
THE POLYMORPHISM OF CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 9 GENE MAY CONTRIBUTE TO RISK OF IMMUNE THROMBOCYTOPENIA
EHA Learning Center, Zi Sheng, 215694
THE IMPACT OF HIGH MOBILITY GROUP BOX 1 IN THE PATHOGENESIS OF IMMUNE THROMBOCYTOPENIA
EHA Learning Center, Mehmet Baysal, 215709
WHAT ARE THE UNDERLYING CAUSES AND CLINICAL CHARACTERISTICS OF CHILDREN WITH REACTIVE THROMBOCYTOSIS AT A KOREAN TERTIARY MEDICAL CENTER?
EHA Learning Center, Ye Jee Shim, 215710
VENETOCLAX IMPROVES QUALITY OF LIFE FOR PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Tara Cochrane, 215726
NO ASSOCIATION BETWEEN INDOOR RADON AND CHILDHOOD LEUKEMIA IN FRECCLE (FINNISH REGISTER-BASED CASE-CONTROL STUDY OF CHILDHOOD LEUKEMIA)
EHA Learning Center, Atte Nikkilä, 215727
IMPROVEMENT OF THE MULTIDISCIPLINARY MANAGEMENT OF SICKLE CELL DISEASE PATIENTS: IMPLEMENTATION OF A SICKLE CELL DISEASE PATIENT’S CLINICAL DATABASE: BELGIAN REGISTER OF SICKLE CELL DISEASE PATIENTS
EHA Learning Center, Beatrice Gulbis, 215743
VARIATIONS IN COMPLICATIONS RELATED TO VASO-OCCLUSIVE CRISES AND HYDROXYUREA USE IN PATIENTS WITH SICKLE CELL DISEASE: OBSERVATIONS FROM STUDIES IN THE USA, SPAIN AND THE GULF REGION
EHA Learning Center, Elena Cela, 215744
EFFICACY AND SAFETY OF DEFIBROTIDE BY VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) DIAGNOSTIC CRITERIA IN AN EXPANDED-ACCESS (T-IND) STUDY
EHA Learning Center, Selim Corbacioglu, 215759
PLASMA PRESEPSIN LEVEL IS A PREDICTIVE MARKER OF SEVERE ACUTE GVHD AFTER ALLO-HSCT: USEFULNESS AS A BIOMARKER OF ALLO-HSCT RELATED COMPLICATION
EHA Learning Center, Tatsuo Oyake, 215760
REGRESSION TREE BASED MODEL FOR PREDICTING NON-RELAPSE MORTALITY IN AML PATIENTS ALLO-TRANSPLANTED IN FIRST COMPLETE REMISSION
EHA Learning Center, Anish Puliyayil, 215775
COMPARISON OF BUSULFAN/CYCLOPHOSPHAMIDE ALONE AND IN COMBINATION WITH THIOTEPA OR ANTI-THYMOCYTE GLOBULIN ON HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOME AMONG BETA-THALASSEMIA PATIENTS
EHA Learning Center, Saqib Ansari, 215776
MURINE MODELS FOR ESTABLISHING STEROID REFRACTORY GVHD
EHA Learning Center, Tomomi Toubai, 215790
LOW-DOSE INTERLEUKIN-2 RESTORING HUMAN REGULATORY T CELL FUNCTION IN VITRO AS A POTENTIAL APPLICATION FOR GVHD THERAPY AFTER TRANSPLANTATION
EHA Learning Center, Tzeon-Jye Chiou, 215791
HYPOFRACTIONATED TOTAL LYMPHOID IRRADIATION BY HELICAL TOMOTHERAPY AND HIGH DOSE CHEMOTHERAPY AS CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA
EHA Learning Center, Fabio Guolo, 215792
MUTATION SPECTRUM IN HBB, HBA1 AND HBA2 GENES IN PATIENTS FROM EUROPEAN PART OF RUSSIA
EHA Learning Center, Svetlana Mann, 215807
COMPREHENSIVE SCREENING FOR COEXISTING HETEROZYGOUS Α0-THALASSEMIA IN HEMOGLOBIN E TRAIT
EHA Learning Center, Piroonrut Wongprachar, 215808
ARE ALL DIRECT ORAL ANTICOAGULANTS EQUAL TO SAFETY AND EFFICACY?
EHA Learning Center, Begoña Navarro Almenzar, 215809
QUALITY CONTROL IN CRYOPRESERVED POOLED PLATELETS: 9-YEAR EXPERIENCE IN A TRANSFUSION CENTRE.
EHA Learning Center, Pablo Romero Garcia, 215823
BACTERIAL CONTAMINANTS AND BIOFILMS EFFECT PLATELET ACTIVATION AND FUNCTION: IMPLICATIONS IN PLATELET TRANSFUSIONS
EHA Learning Center, Joels Wilson-Nieuwenhuis, 215824
ALLOIMMUNIZATION TO D AND NON-D RHESUS ANTIGENS INDUCED BY PLATELET TRANSFUSIONS
EHA Learning Center, Michael Daskalakis, 215825
NIVOLUMAB TREATMENT DISCONTINUATION IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY EXPERIENCE
EHA Learning Center, Liudmila Fedorova, 215903
RELEVANCE OF PRE AND POST TRANSPLANT PET AND HASENCLEVER INDEX IN PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANT FOR HODGKIN LYMPHOMA
EHA Learning Center, Siddharth Turkar, 215904
A REAL WORLD STUDY OF CLINICAL CHARACTERISTICS AND TREATMENT OUTCOME OF HODGKIN LYMPHOMA IN MALAYSIA: A SINGLE CENTER EXPERIENCE IN A RESOURCE LIMITED SETTING
EHA Learning Center, Tze Shin Leong, 215905
ALLOGENEIC STEM CELL TRANSPLANTATION OVERCOMES THE NEGATIVE PROGNOSTIC IMPACT OF ASXL1 MUTATIONS IN TRANSPLANT ELIGIBLE PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA.
EHA Learning Center, Abhishek Mangaonkar, 215919
HEMATOLOGICAL PHENOTYPES OF DIFFERENT ALPHA-THALASSAEMIA GENOTYPES CAUSING HYPOCHROMIC MICROCYTIC ANEMIA AT NEONATAL PERIOD
EHA Learning Center, thidarat suksangpleng, 215920
INVOLVEMENT OF LEUCOCYTE DERIVED EXTRACELLULAR VESICLES IN THE PROCOAGULANT STATE FOUND IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA-RELATED CONDITION
EHA Learning Center, Adeline Wannez, 215921

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings